FDA approval of the selective HIF2α inhibitor belzutifan for advanced phaeochromocytoma and paraganglioma (PPGL) is an important milestone in precision oncology. This achievement underscores the power of scientific collaboration in establishing HIF2α as a central driver of PPGL pathogenesis and offers hope for a historically underserved group of patients.
- Carlota Arenillas
- Rodrigo A. Toledo
